
-
Philippines biodiversity hotspot pushes back on mining
-
Deal or no deal: What happens with Trump's July tariff deadline?
-
Canada turns to drones for reforestation after wildfires
-
US, Japan, India, Australia pledge mineral cooperation on China jitters
-
Son of kingpin 'El Chapo' to plead guilty to drug trafficking in US
-
Trump urges 60-day Gaza ceasefire deal ahead of Netanyahu visit
-
Partial verdict in Combs trial, jury will keep deliberating
-
Djokovic thanks 'miracle pills' after Wimbledon win
-
US college bans transgender athletes following swimming furor
-
Global stocks mixed as markets track US trade deal prospects
-
Djokovic up and running at Wimbledon in bid for Grand Slam history
-
Jury reaches partial verdict in Sean "Diddy" Combs trial
-
Giroud signs one-year deal with Ligue 1 club Lille
-
Gauff vows to make changes after shock Wimbledon exit
-
Gonzalo heads Real Madrid past Juventus and into Club World Cup quarters
-
Gauff crashes out of Wimbledon on day of shocks
-
Big automakers report US sales jump on pre-tariff consumer surge
-
'Alone' Zverev considers therapy after shock Wimbledon exit
-
Second seed Coco Gauff knocked out of Wimbledon
-
Switzerland comes to the aid of Red Cross museum
-
'That's life': No regrets for former champion Kvitova after Wimbledon farewell
-
AI videos push Combs trial misinformation, researchers say
-
UK govt guts key welfare reforms to win vote after internal rebellion
-
Polish supreme court ratifies nationalist's presidential vote win
-
Macron, Putin discuss Iran, Ukraine in first talks since 2022
-
French league launches own channel to broadcast Ligue 1
-
Man City left to reflect on Club World Cup exit as tournament opens up
-
Shock study: Mild electric stimulation boosts math ability
-
Europe swelters as surprise early summer heatwave spreads
-
Third seed Zverev stunned at Wimbledon
-
Israel expands Gaza campaign ahead of Netanyahu's US visit
-
Gaza mourns those killed in Israeli strike on seafront cafe
-
Rubio hails end of USAID as Bush, Obama deplore cost in lives
-
Berlusconi family sell Monza football club to US investment fund
-
UN aid meeting seeks end to Global South debt crisis
-
Trump ramps up Musk feud with deportation threat
-
French paparazzi boss handed 18-month suspended sentence for blackmail
-
Gilgeous-Alexander agrees record $285 mln extension: reports
-
Tearful former champion Kvitova loses on Wimbledon farewell
-
IMF urges Swiss to strengthen bank resilience
-
Sri Lanka eye top-three spot in ODI rankings
-
Trump hails new 'Alligator Alcatraz' migrant detention center
-
US Senate approves divisive Trump spending bill
-
Krejcikova toughs it out in Wimbledon opener, Sinner cruises
-
UK govt braces for crunch welfare reforms vote amid major rebellion
-
Shifting to Asia, Rubio meets Quad and talks minerals
-
Stocks diverge while tracking US trade deal prospects
-
Bruce Lee Club closes archive doors citing operating costs
-
Trump ramps up Musk feud with deportation, DOGE threats
-
BTS announces comeback for spring 2026

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN